Merck & Co INC (MRK) Shareholder Sphera Funds Management LTD Has Boosted Its Holding by $6.00 Million as Share Price Rose

Merck & Co., Inc. (NYSE:MRK) LogoInvestors sentiment is 1 in 2018 Q2. Its the same as in 2018Q1. It has no change, as 48 investors sold MRK shares while 608 reduced holdings. only 126 funds opened positions while 530 raised stakes. 1.88 billion shares or 1.46% less from 1.91 billion shares in 2018Q1 were reported. First Merchants holds 6,354 shares or 0.07% of its portfolio. Family holds 0.55% or 20,232 shares in its portfolio. Macnealy Hoover Invest Incorporated owns 18,108 shares or 0.85% of their US portfolio. Vident Advisory Ltd Liability Company accumulated 0.14% or 60,264 shares. Acr Alpine Cap Research Limited holds 0.03% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 9,731 shares. Perigon Wealth Limited Co has invested 2.57% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Semper Augustus Invs Group Ltd holds 1.62% or 42,723 shares in its portfolio. Bb&T holds 545,428 shares or 0.63% of its portfolio. St Johns Invest Mngmt Ltd Com reported 18,780 shares. Beach Inv Counsel Incorporated Pa invested in 79,029 shares or 0.5% of the stock. First National Bank Of Mount Dora Trust Invest Svcs has invested 1.81% in Merck & Co., Inc. (NYSE:MRK). North Star Asset Mgmt invested in 0.06% or 11,765 shares. Sector Gamma As accumulated 913,830 shares or 9.22% of the stock. New York-based Gabalex Capital Llc has invested 1.79% in Merck & Co., Inc. (NYSE:MRK). Chickasaw Cap Limited Liability invested in 35,238 shares or 0.05% of the stock.

Sphera Funds Management Ltd increased its stake in Merck & Co Inc (MRK) by 17.24% based on its latest 2018Q2 regulatory filing with the SEC. Sphera Funds Management Ltd bought 100,000 shares as the company’s stock rose 11.62% with the market. The institutional investor held 680,000 shares of the health care company at the end of 2018Q2, valued at $41.28M, up from 580,000 at the end of the previous reported quarter. Sphera Funds Management Ltd who had been investing in Merck & Co Inc for a number of months, seems to be bullish on the $206.31B market cap company. The stock increased 1.84% or $1.43 during the last trading session, reaching $79.34. About 21.36 million shares traded or 92.63% up from the average. Merck & Co., Inc. (NYSE:MRK) has risen 6.72% since December 2, 2017 and is uptrending. It has underperformed by 8.90% the S&P500.

Sphera Funds Management Ltd, which manages about $725.36 million US Long portfolio, decreased its stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 103,901 shares to 145,096 shares, valued at $19.18M in 2018Q2, according to the filing. It also reduced its holding in Shire Plc (NASDAQ:SHPG) by 70,000 shares in the quarter, leaving it with 126,500 shares, and cut its stake in Reata Pharmaceuticals Inc.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: which released: “Friday’s Vital Data: McDonald’s, Twitter and Merck – Yahoo News” on November 30, 2018, also with their article: “OncoSec down 56% premarket on mid-stage TAVO data – Seeking Alpha” published on November 06, 2018, published: “A Short-Term Outlook For Merck – Seeking Alpha” on November 26, 2018. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: and their article: “Better Buy: Celgene Corporation vs. Merck & Co. – The Motley Fool” published on November 17, 2018 as well as‘s news article titled: “Merck starts rolling BLA for Ebola vaccine – Seeking Alpha” with publication date: November 13, 2018.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Among 7 analysts covering Merck \u0026 Co (NYSE:MRK), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Merck \u0026 Co has $84 highest and $74 lowest target. $79’s average target is -0.43% below currents $79.34 stock price. Merck \u0026 Co had 9 analyst reports since July 30, 2018 according to SRatingsIntel. The stock of Merck & Co., Inc. (NYSE:MRK) has “Buy” rating given on Monday, October 29 by SunTrust. The company was maintained on Tuesday, October 16 by Citigroup. The firm has “Overweight” rating by Morgan Stanley given on Thursday, August 23. The firm earned “Buy” rating on Monday, July 30 by Bank of America. Barclays Capital maintained the shares of MRK in report on Friday, September 7 with “Overweight” rating. The stock of Merck & Co., Inc. (NYSE:MRK) has “Outperform” rating given on Thursday, October 11 by Credit Suisse. The stock of Merck & Co., Inc. (NYSE:MRK) has “Overweight” rating given on Friday, October 12 by Barclays Capital. BMO Capital Markets maintained Merck & Co., Inc. (NYSE:MRK) rating on Monday, October 22. BMO Capital Markets has “Outperform” rating and $82 target. The firm has “Buy” rating given on Wednesday, October 31 by Citigroup.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.